๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Asthma
Clinical trial register · China

Asthma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 17 Beijing 16 Shanghai 15 Chengdu 8 Changsha 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Sanofi3 Guangdong Hengrui Pharmaceutical Co., Ltd2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2 First Affiliated Hospital of Ningbo University2
Site location
Guangzhou17 Beijing16 Shanghai15 Chengdu8 Changsha7
All 58 locations
Target enrolment
to

Asthma trials in China

39 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Childhood Infection and Immunity Longitudinal Cohort
NCT07815925Immunity, Respiratory Infection, Asthma
Zhejiang Provincial Center for Disease Control and Prevention
Observational
1,200
Dongyang, Yiwu
2026-09-10
Recruiting
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
NCT07823842Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Shanghai Pulmonary Hospital, Shanghai, China
Observational
538
Shanghai
2026-07-30
Recruiting
Efficacy and Safety of CHF 5993 100/6/12.5 ฮผg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting รŸ2-agonists
NCT07546981Asthma
Chiesi Farmaceutici S.p.A.
Phase 3
554
Beijing
2026-06-26
Not yet open
Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma
NCT07453771Allergic Rhinitis, Asthma
The Affiliated Hospital of Qingdao University
Not applicable
18
Guangzhou, Qingdao, Taiโ€™an, Chongqing
2026-03-05
Not yet open
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
NCT07436221Asthma
DrugAK139
Akeso
Phase 2
160
Guangzhou, Shanghai
2026-02-28
Recruiting
Multimodal Tongue-Pulse Information Fusion for Syndrome Diagnosis and Cohort Study in Children With Asthma
NCT07383883Asthma
Shanghai Children's Medical Center
Observational
1,000
Shanghai
2026-02-01
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma
NCT07589439Asthma
Shanghai Novamab Biopharmaceuticals Co., Ltd.
Phase 2
216
Shanghai
2025-09-30
Recruiting
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
NCT07098403Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 3
408
Guangzhou
2025-09-03
Recruiting
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
NCT07011524Asthma
Keymed Biosciences Co.Ltd
Phase 2
200
Guangzhou
2025-08-19
Recruiting
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
NCT07313904Environmental Exposure, Asthma, Bronchiectasis, ABPA
First Affiliated Hospital of Ningbo University
Observational
125
Ningbo
2025-07-23
Recruiting
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma
NCT07015749Asthma
DrugIBI3002
The First Affiliated Hospital of Soochow University
Phase 1
12
Suzhou
2025-06-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugPF-07275315
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Not yet open
Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma
NCT06940700Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
60
Chengdu
2025-04
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
NCT06837922Asthma
Shanghai Mabgeek Biotech.Co.Ltd
Phase 3
504
Guangzhou
2025-03-25
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784Asthma
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025Asthma
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Active, closed
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
NCT06680947Asthma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
225
Shanghai
2024-12-20
Recruiting
Remote Anxiety Management for ICS-resistant Asthma Study
NCT06732141Asthma
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
By invitation
Intervention Effects of High-intensity Tai Chi in Mild or Moderate Asthma
NCT06728904Asthma
Yufen Wu, MD
Not applicable
35
Shanghai
2024-12-10
Not yet open
Clinical Study on the Treatment of Chronic Airway Diseases (Asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie
NCT06691802Chronic Obstructive Pulmoriary Disease (COPD), Asthma
Henan University of Traditional Chinese Medicine
Not applicable
2,312
Zhengzhou
2024-12
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Recruiting
Efficacy and Safety Study of 610 in Patients With Severe Asthma
NCT06323213Asthma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
480
Shanghai
2024-06-24
Recruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257Asthma
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
Expressions of Ezrin and Pip5k1ฮฑ Proteins in Airway Smooth Muscle of Asthmatic Patients
NCT06427018Asthma, Protein
Lei-Miao Yin
Observational
120
Shanghai
2024-05-28
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Active, closed
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496Asthma
GlaxoSmithKline
Phase 4
1,366
Chancheng District, Liwan District, North Street, Nanshan District, Zhuhai
2024-04-16
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413Asthma
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
By invitation
Treatable Traits of Severe Asthma
NCT06811740Asthma
Beijing Chao Yang Hospital
Not applicable
160
Beijing
2024-01-01
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
NCT05593250Asthma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
260
Guangzhou
2023-01-17
Recruiting
The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma
NCT05496582Asthma
Shanghai University of Traditional Chinese Medicine
Observational
100
Changsha, Shanghai
2022-11-01
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
DrugDupilumab
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/asthma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies listing the condition Asthma.

How many Asthma trials are recruiting in China?

24 of the 39 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 7 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Asthma), 39 studies
PhaseStudiesRecruitingShare
Phase 211528.2%
Observational9723.1%
Phase 39923.1%
Not applicable7217.9%
Phase 4205.1%
Phase 1112.6%

Most active sponsors

Lead sponsors with the most studies (Asthma)
Lead sponsorStudiesRecruiting
AstraZeneca65
Sanofi30
Beijing Chao Yang Hospital21
First Affiliated Hospital of Ningbo University22
GlaxoSmithKline21
Guangdong Hengrui Pharmaceutical Co., Ltd21
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.21
Akeso10
Chiesi Farmaceutici S.p.A.11
China-Japan Friendship Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.